Unlike typical autoimmune drugs that block or suppress the immune system, Nektar's ResPeg works by increasing anti-inflammatory cells. This mechanism allows for a marketing narrative centered on "restoring balance" rather than "inhibition," which can be more appealing and reassuring to patients wary of suppressing their immune system.
While the gut instinct is that patients prefer daily pills over injections, this preference flips when the injection is highly infrequent. For chronic conditions, a quarterly shot (four per year) is often viewed as more convenient and favorable by patients than the burden of a daily oral medication, challenging conventional wisdom on administration routes.
Unlike conditions with transient flare-ups, missing a few doses of a fast-acting alopecia drug can cause catastrophic hair loss, erasing years of progress. A long-acting injectable provides a crucial buffer against real-world issues like insurance delays, making it a uniquely superior option for patients despite the injection route.
The market initially wrote off ResPeg for alopecia after 36-week data seemed inferior to fast-acting JAK inhibitors. However, 52-week data showed ResPeg's efficacy eventually hurdled the competition. This highlights the risk of prematurely judging chronic disease therapies that may require longer treatment durations to show their full benefit.